TransMedics Group, Inc. (TMDX) witnessed a significant surge in its stock price, soaring 6.77% in the pre-market session on Friday. This impressive rally was fueled by the company's exceptional fourth-quarter 2024 financial results and a robust outlook for the year 2025.
The medical technology company reported better-than-expected earnings and revenue for the fourth quarter. Earnings per share came in at $0.19, surpassing analysts' estimates of $0.18. Revenue skyrocketed 49.83% year-over-year to $121.62 million, significantly exceeding the consensus estimate of $110.29 million.
TransMedics Group's strong performance was driven by robust demand for its products and services, as well as operational efficiency and improved profitability. The company reported a gross margin of 59% and achieved positive income from operations and net income, further bolstering investor confidence.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。